Market closedNon-fractional
Vertex Pharmaceuticals/VRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
VRTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
5,400
Website
www.vrtx.com
VRTX Metrics
BasicAdvanced
$127B
Market cap
31.94
P/E ratio
$15.41
EPS
0.39
Beta
-
Dividend rate
Price and volume
Market cap
$127B
Beta
0.39
Financial strength
Current ratio
3.501
Quick ratio
3.152
Long term debt to equity
3.889
Total debt to equity
3.889
Interest coverage (TTM)
102.08%
Management effectiveness
Return on assets (TTM)
12.81%
Return on equity (TTM)
24.38%
Valuation
Price to earnings (TTM)
31.944
Price to revenue (TTM)
12.465
Price to book
6.86
Price to tangible book (TTM)
7.65
Price to free cash flow (TTM)
36.488
Growth
Revenue change (TTM)
10.61%
Earnings per share change (TTM)
22.82%
3-year revenue growth (CAGR)
16.66%
3-year earnings per share growth (CAGR)
13.67%
What the Analysts think about VRTX
Analyst Ratings
Majority rating from 31 analysts.
VRTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.7B
6.87%
Net income
$1.1B
13.50%
Profit margin
40.86%
6.21%
VRTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$3.89
$4.08
$4.20
$4.76
-
Expected
$3.88
$3.97
$4.10
$4.06
$4.16
Surprise
0.21%
2.67%
2.37%
17.15%
-
VRTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $127B as of July 27, 2024.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 31.94 as of July 27, 2024.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Vertex Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.